Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
GSK authors: Barbara J Klencke, MD; Sunhee Ro, PhD; Rafe Donahue, PhD; Jun Kawashima, MD
